Publisher's Synopsis
This short volume provides a comprehensive review of the current state of risk assessment for ventricular arrhythmias. All current techniques are evaluated as to their efficacy, or identifying patients who may benefit from specific anti–arrhythmic therapies such as drugs, surgery, or the implantable cardioverter defibrillator. Included in the evaluation is the risk–benefit and cost–benefit relationship of using these treatments. The first part of the book discusses risk assessment in patients with coronary artery disease while the latter part is devoted to risk assessment in patients with ventricular tachyarrhythmias due to other etiologies.
This comprehensive evaluation of current methods for risk assessment for ventricular arrhythmias will be of great value to all cardiology professionals, especially within the current political health care climate.
